Can GnRH Agonist Trigger Prevent Ovarian Hyperstimulation Syndrome?

• Status: Terminated
• Trial end date: 2014-01-01
• Target enrollment: 0
• Participant gender: Female

Summary

Ovarian hyperstimulation syndrome (OHSS) is a major complication of ovarian stimulation for IVF if hCG is used to trigger final oocyte maturation. The investigators propose that using GnRH agonist as a trigger will eliminate OHSS, even in high-risk patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Elisha Hospital
• Collaborator: Merck Sharp & Dohme Corp.
• Treatments: Deslorelin; Triptorelin Pamoate

Criteria

Inclusion Criteria:

• A female patient who needs IVF to become pregnant.

• Regular menstrual cycle.

• Antral follicular count (AFC) > 18

• Following treatment with follitropin beta more than 18 follicles ≥ 11 mm will develop.

Exclusion Criteria:

• Hypersensitivity to the active substance or to any of the medications used.

• Tumors of the ovary, breast, uterus, pituitary or hypothalamus.

• Pregnancy.

• Abnormal (not menstrual) vaginal bleeding without a known/diagnosed cause.

• Primary ovarian failure.

• Ovarian cysts or enlarged ovaries.

• A history of Ovarian Hyperstimulation Syndrome (OHSS).

• A previous COS cycle that resulted in more than 30 follicles > 11 mm measured by ultrasound examination.

• Fibroid tumours of the uterus incompatible with pregnancy.

• Malformations of the reproductive organs incompatible with pregnancy